Elevated serum interleukin-6 (IL-6) in Hodgkin lymphoma (HL) is reported to correlate with B symptoms, response rate and survival in adult patients. The authors studied prognostic significance of IL-6 expression by immunohistochemistry on Hodgkin-Reed Sternberg cells and background reactive cells in a retrospective cohort of pediatric HL patients treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) from January 2009 through December 2013. Of 142 patients, tissue blocks were retrieved in 110 patients. On logistic regression analysis, IL-6 expression on background cells alone was among the factors associated with inferior response rate (OR-9.9, 95%CI-1.2, 78.3; p = 0.03). On multivariate analysis, IL-6 expression on background cells alone had significant impact on 5 y freedom from treatment failure (FFTF) (HR-7.7, 95% CI-1.2, 48.6; p = 0.03). IL-6 expression by immunohistochemistry in the background cells is an independent poor predictor of response and FFTF in pediatric HL. Further prospective studies in children are needed to confirm the current findings and whether IL-6 expression can be used to stratify treatment.
Interleukin-6 Pediatric Hodgkin lymphoma
This is a preview of subscription content, log in to check access.
Compliance with Ethical Standards
Conflict of Interest
Mauz-Körholz C, Metzger ML, Kelly KM, et al. Pediatric hodgkin lymphoma. J Clin Oncol. 2015;33:2975–85.CrossRefGoogle Scholar
Cozen W, Gill PS, Ingles SA, et al. IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood. 2004;103:3216–21.CrossRefGoogle Scholar
Marri PR, Hodge LS, Maurer MJ, et al. Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma. Clin Cancer Res. 2013;19:6812–9.CrossRefGoogle Scholar
Casasnovas R-O, Mounier N, Brice P, et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin’s lymphoma: a study from the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2007;25:1732–40.CrossRefGoogle Scholar
Reynolds GM, Billingham LJ, Gray LJ, et al. Interleukin 6 expression by Hodgkin/reed-Sternberg cells is associated with the presence of “B” symptoms and failure to achieve complete remission in patients with advanced Hodgkin’s disease. Br J Haematol. 2002;118:195–201.CrossRefGoogle Scholar
Bhethanabhotla S, Jain S, Kapoor G, et al. Outcome of pediatric advanced Hodgkin lymphoma treated with ABVD and predictors of inferior survival: a multicenter study of 186 patients. Leuk Lymphoma. 2017;58:1617–23.CrossRefGoogle Scholar
Olweny CL. Cotswolds modification of the Ann Arbor staging system for Hodgkin’s disease. J Clin Oncol. 1990;8:1598.CrossRefGoogle Scholar
Blay JY, Farcet JP, Lavaud A, Radoux D, Chouaïb S. Serum concentrations of cytokines in patients with Hodgkin’s disease. Eur J Cancer. 1994;30A:321–4.CrossRefGoogle Scholar
Seymour JF, Talpaz M, Hagemeister FB, Cabanillas F, Kurzrock R. Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin’s disease. Am J Med. 1997;102:21–8.CrossRefGoogle Scholar
Gorschlüter M, Bohlen H, Hasenclever D, Diehl V, Tesch H. Serum cytokine levels correlate with clinical parameters in Hodgkin’s disease. Ann Oncol. 1995;6:477–82.CrossRefGoogle Scholar
Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235–8.CrossRefGoogle Scholar